DB18460InvestigationalProtein Based Therapies
Eftansomatropin alfa (GX-H9) comprises a recombinant human growth hormone fused to hyFc, a synthetic hybrid Fc fragment. It is under investigation for the treatment of growth hormone deficiency.
- Code names
- GX-H9
Resolves to
Compound
What you can answer from here — as of September 26, 2023
Which companies are running trials of Eftansomatropin alfa, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account